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Background: The vast majority of first-time coronary angiography patients do not have obstructive CAD. We previously validated a peripheral blood 
gene expression score (GES), consisting of 23 genes, age, and sex, which can assess obstructive CAD likelihood in non-diabetic patients, but the 
subsequent clinical course is largely unknown.
Methods: Patients from the PREDICT trial (NCT00500617), clinically indicated for invasive angiography, were followed for 1 year from index 
procedure and associated GES. The primary endpoint was MACE (myocardial infarction, stroke/TIAs, death) and revascularization at 30 days and 12 
months. The relations between GES and these endpoints were assessed.
Results: From 1160 patients with angiographic and GES results, 1116 (96%) completed follow-up. The primary endpoint rate was 23% at 30 days 
and an additional 2.2% at 12 months. GES was positively associated with the primary endpoint (p< 0.001; OR = 5.5 for GES >28 vs. ≤15) and 
added to clinical risk scores (Framingham and Diamond-Forrester) by logistic regression. MACE incidence was 1.5% (17/1116) and only 3/17 had 
GES ≤15. The 396 patients with GES ≤15, had a primary endpoint negative predictive value of 90% and >99% for MACE alone.
Conclusions: The GES identified patients who were free of obstructive CAD, and were highly unlikely to suffer an adverse cardiovascular event or 
procedure within 12 months. This non-invasive method is useful for CAD patient risk stratification, especially in identifying low risk individuals.
 
